findmyKOL

Al Benson, MD

Enriched profile

Professor of Medicine, Division of Hematology and Oncology; Director for Cooperative Groups · Northwestern University Feinberg School of Medicine

ORCIDNPI
Region🇺🇸 Chicago, IL · Midwest · United StatesSpecialtyMedical OncologyFocusColorectal Cancer Treatments and Studies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1987–2026

Al Benson is Professor of Medicine, Division of Hematology and Oncology; Director for Cooperative Groups at Northwestern University Feinberg School of Medicine. OpenAlex indexes 811 publications with 74,238 citations (h-index 132); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Al B. Benson III, MD, is Professor of Medicine, Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center. The public record shows 811 publications with 74,238 citations (h-index 132), centered on Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Colorectal Cancer Surgical Treatments. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 32 companies, 8 NIH-funded awards (1987–2026).

  • Most recent indexed publication: 2026 · The oncologist
  • Top research focus: Colorectal Cancer Treatments and Studies
  • 16 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 32 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Colorectal Cancer7 trialsRectal Neoplasms6 trialsPancreatic Cancer2 trialsHepatobiliary Cancer2 trialsGastroesophageal Cancer2 trialsStomach Neoplasms2 trialsColonic Neoplasms1 trialAnus Neoplasms1 trialBreast Cancer1 trialLung Cancer (NSCLC/SCLC)1 trialBladder / Urothelial Cancer1 trialKidney Cancer / RCC1 trialKidney Neoplasms1 trialAdenocarcinoma, Mucinous1 trialNeoplasm Metastasis1 trialCarcinoma, Neuroendocrine1 trialEsophageal Neoplasms1 trialDiarrhea1 trialNeuroendocrine Tumors1 trialCarcinoid Tumor1 trial

Research focus

OpenAlex concept fingerprint
Colorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesColorectal Cancer Surgical TreatmentsPancreatic and Hepatic Oncology ResearchHepatocellular Carcinoma Treatment and Prognosis

Drugs & molecules

across trials, industry payments and publications
FluorouracilClinical trials2Industry paymentsPublications5LeucovorinClinical trials1Industry paymentsPublications4Keytrudageneric · PembrolizumabClinical trialsIndustry payments1Publications3

Works with

trial sponsors and companies reporting payments
Boston Scientific CorporationClinical trials1Industry payments2E.R. Squibb & Sons, L.L.C.Clinical trialsIndustry payments13Incyte CorporationClinical trialsIndustry payments11

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
811publications

Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.

74,238citations

Total citations across indexed works.

132h-index

Hirsch index (OpenAlex). i10-index 408.

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials
32companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
8NIH grants · 1987–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    64.6%
    PD-1 inhibitor32%
    Nivolumab100%
    Part B, office-administered18 patients
    CD38-directed Cytolytic Antibody29.6%
    Daratumumab100%
    Part B, office-administered25 patients
  • Dermatology

    14.2%
    Corticosteroid14.2%
    Methylprednisolone sodium succinate100%
    Part B, office-administered21 patients
  • Metabolism & gastrointestinal

    10.3%
    Other antiemetics9%
    Fosaprepitant100%
    Part B, office-administered12 patients
    Serotonin-3 Receptor Antagonist1.2%
    Palonosetron hcl100%
    Part B, office-administered24 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

8 NIH research awards on record, funded 19872026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

160 congress contributions (2003–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Mary F. Mulcahy137Leonard B. Saltz76Alan P. Venook68

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/al-benson-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/LurieCancer/status/1754597557223727325

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chair

    NCCN Hepatobiliary Guidelines Panel

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu
  • Chair

    NCCN Colon, Rectal and Anal Panel

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu
  • Executive Committee Member and past-Chair

    Board of Directors, National Comprehensive Cancer Network (NCCN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.